Published in Adv Pharm Bull on December 31, 2015
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
Protein production and purification. Nat Methods (2008) 3.97
Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol (2014) 2.40
Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif (2000) 1.32
Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol (2003) 1.32
Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol (2002) 1.29
Metabolic responses to cachectin/TNF. A brief review. Ann N Y Acad Sci (1990) 1.28
Sleep. A physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci (1998) 1.08
How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system. Spectroscopic evidence for highly efficient refolding of a single-chain Fv fragment. J Biol Chem (2003) 1.08
Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology (2003) 1.01
Bacterial expression and purification of interleukin-2 tyrosine kinase: single step separation of the chaperonin impurity. Protein Expr Purif (2008) 0.98
A fast mutagenesis procedure to recover soluble and functional scFvs containing amber stop codons from synthetic and semisynthetic antibody libraries. J Immunol Methods (2006) 0.91
Isolation of an scFv targeting BRG1 using phage display with characterization by AFM. Biochem Biophys Res Commun (2006) 0.90
Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for) Inflamm Bowel Dis (2000) 0.85
A fluorescent, genetically engineered microorganism that degrades organophosphates and commits suicide when required. Appl Microbiol Biotechnol (2009) 0.84
Anti-TNF-alpha therapy and systemic vasculitis. Mediators Inflamm (2014) 0.84
Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol (2014) 0.83
[Soluble expression and target study to brain of anti-TfR ScFv]. Sheng Wu Gong Cheng Xue Bao (2004) 0.81
Stationary phase protein overproduction is a fundamental capability of Escherichia coli. Biochem Biophys Res Commun (2004) 0.81
High-level expression and rapid purification of rare-codon genes from hyperthermophilic archaea by the GST gene fusion system. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.80
Prokaryotic expression, purification and functional characterization of human FHL3. Biotechnol Lett (2009) 0.79
A strategy for high-level expression of a single-chain variable fragment against TNFα by subcloning antibody variable regions from the phage display vector pCANTAB 5E into pBV220. Protein Expr Purif (2010) 0.79
Production and characterization of a bacterial single-chain antibody fragment specific to B-cell-activating factor of the TNF family. Protein Expr Purif (2005) 0.79
Anti-TNF therapies--the hope of tomorrow. Clin Dermatol (2002) 0.79
Potential roles for tumour necrosis factor alpha during embryonic development. Anat Embryol (Berl) (1995) 0.79
Ovarian actions of tumor necrosis factor-alpha (TNF alpha): pleiotropic effects of TNF alpha on differentiated functions of untransformed swine granulosa cells. Endocrinology (1991) 0.77
Investigating the mutagenic effects of three commonly used pulpotomy agents using the ames test. Adv Pharm Bull (2015) 0.78
Identification of Novel Single Chain Fragment Variable Antibodies Against TNF-α Using Phage Display Technology. Adv Pharm Bull (2015) 0.75